Spinal presentations in children with spinal muscular atrophy type 1 following gene therapy treatment with onasemnogene abeparvovec – The SMA REACH UK network experience
Neuromuscular Disorders · 2024-11 · 44 · 104451
DOI: 10.1016/j.nmd.2024.104451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuromuscular Disorders, 2024-11. Verfasst von Amy Wolfe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Neurology - Neuromuscular Service, Evelina London Children's Hospital, Guy's & St Thomas' NHS Foundation Trust, London, UK; …. Hauptthemen laut MEDLINE: Genetic Therapy, Spinal Muscular Atrophies of Childhood. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Muscular Dystrophy UK, University College London, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Spinal muscular atrophy (SMA) is a neuromuscular disorder of mainly early onset and variable severity. Prior to the introduction of disease modifying therapies (DMTs), children with SMA type 1 typically died before 2 years of age and management was primarily palliative. Onasemnogene abeparvovec (OA), nusinersen, and risdiplam are novel DMTs which ameliorate the effects of the underlying genetic defect at least partially making SMA a treatable condition. Survival and achievement of previously unmet developmental milestones result in treated SMA type 1 children spending more time upright than expected based on the natural history of the treatment-naïve condition. Consequently, spinal asymmetry and kyphosis, features not typically seen in untreated SMA type 1 children due to early mortality, are increasingly common complications. Precise data regarding their prevalence, severity, and management are currently limited. This study describes the spinal features and management in 75 children with SMA type 1 who received OA between March 2021 and December 2022. Retrospective analysis from SMA REACH UK data showed that 44/75 (59 %) clinically had spinal asymmetry and 37 (49 %) had kyphosis. This study aims to raise awareness of this important feature as part of the changed natural history of SMA type 1 post OA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatric Neurology - Neuromuscular Service, Evelina London Children's Hospital, Guy's & St Thomas' NHS Foundation Trust, London, UK; Dubowitz Neuromuscular Centre, Great Ormond Street Hospital for Childr…
- Department of Paediatric Neurology - Neuromuscular Service, Evelina London Children's Hospital, Guy's & St Thomas' NHS Foundation Trust, London, UK.
- Department of Paediatrics - Respiratory Medicine, Evelina London Children's Hospital, Guy's & St Thomas' NHS Foundation Trust, London, UK.
- Dubowitz Neuromuscular Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, WC1N 3JH, UK.
- Institute of Child Health, University College London, Gower St, London WC1E 6BT, UK.
- Department of Paediatric Neurology - Neuromuscular Service, Evelina London Children's Hospital, Guy's & St Thomas' NHS Foundation Trust, London, UK; Randall Centre for Cell and Molecular Biophysics, Muscle Signalling Se…
Förderung
- Muscular Dystrophy UK
- University College London
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Medical Research Council
- SMA Trust
- Great Ormond Street Hospital for Children
Zitieren
APA
Wolfe, A., Sheehan, J., Schofield, A., Cranney, H., O'Reilly, E., Stimpson, G., Andrews, A., Vanegas, M., Lucas, J., Scoto, M., Gowda, V., Wraige, E., Jungbluth, H., & SMA REACH UK network (2024). Spinal presentations in children with spinal muscular atrophy type 1 following gene therapy treatment with onasemnogene abeparvovec – The SMA REACH UK network experience. Neuromuscular Disorders, 44, 104451. https://doi.org/10.1016/j.nmd.2024.104451
Vancouver
Wolfe A, Sheehan J, Schofield A, Cranney H, O'Reilly E, Stimpson G, et al. Spinal presentations in children with spinal muscular atrophy type 1 following gene therapy treatment with onasemnogene abeparvovec – The SMA REACH UK network experience. Neuromuscular Disorders. 2024;44:104451. doi:10.1016/j.nmd.2024.104451
BibTeX
@article{Wolfe2024,
author = {Wolfe, Amy and Sheehan, Jennie and Schofield, Alex and Cranney, Helen and O'Reilly, Emer and Stimpson, Georgia and Andrews, Alice and Vanegas, Maria and Lucas, Jonathan and Scoto, Mariacristina and Gowda, Vasantha and Wraige, Elizabeth and Jungbluth, Heinz and SMA REACH UK network, SMA REACH UK network},
title = {Spinal presentations in children with spinal muscular atrophy type 1 following gene therapy treatment with onasemnogene abeparvovec – The SMA REACH UK network experience},
journal = {Neuromuscular Disorders},
year = {2024},
volume = {44},
pages = {104451},
doi = {10.1016/j.nmd.2024.104451}
}
EUVIMED